FDA Approves Generic Oral Suspension For Influenza

The US Food and Drug Administration (FDA) has approved Oseltamivir Powder, the first generic oral suspension of Tamiflu (oseltamivir phosphate), for the treatment and prevention of influenza. Oseltamivir Powder can be administered to adult and pediatric patients at 6 mg/ml, and is indicated for influenza types A and B.
______________________________________________________________________
RELATED CONTENT
ACIP Releases Updated Influenza Vaccine Recommendations
Novel Diagnostic Tests Better Predict Flu Virus vs Traditional Ones
______________________________________________________________________
Tamiflu was first approved in 1999 by the FDA, and the generic oseltamivir phosphate was approved in 2016.

Common adverse effects associated with oseltamivir phosphate include nausea and vomiting.

—Melissa Weiss

Reference:

Zydus’ Nesher Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for oral suspension [press release]. Ahmedabad, IN: Zydus Cadila; September 16, 2017. http://zyduscadila.com/wp-content/uploads/2017/09/Zydus-Nesher-Pharmaceuticals-Oseltamivir-POS-gets-final-approval-Sept-2017.pdf. Accessed September 18, 2017.